Starting from available ribose-building blocks, the 4′-C-methyl-, 4′-C-ethyl-and the new 4′-Cpropyl-substituted deoxyuridines were synthesized. Afterwards we converted 4′-C-alkylated-2′-deoxyuridines into the corresponding 4′-C-alkylated-5-iodo-2′-deoxyuridines 3a-c and those in turn into the 4′-C-alkylated-5-iodo-2′-deoxycytidines 4a-c.
Introduction
For a long time, chemically modified nucleoside analogues have been prominent life-saving drugs. This pharmacologically diverse family, which contains structural features of the skeleton of natural nucleosides, is used for treatment of cancer and viral infections.
1 Along with HIV (human immunodeficiency virus) and HV (hepatitis virus), HSV (herpes simplex virus) and VZV (varicella-zoster virus) are prominent pathogens. In addition to acyclovir and bromovinyldeoxyuridine, HSV and VZV are treated with the approved antiviral drug 2′-deoxy-5-iodouridine 1 (Figure 1) . 1a,d,f,i,2 Compound 1, marketed for example as Stoxil
In addition to 5-halopyrimidine nucleosides, 4′-C-modified nucleosides gained significant interest, because several analogues of this class exhibited antiviral activity.
5 4′-C-modified nucleosides act also as nucleoside reverse transcriptase inhibitors (NRTIs) 5g,h,6 and showed even activity against multi-drug resistant virus strains.
5c,6c The evolution of viral resistance boosts the urgent requirements for new effective drugs and therapies against viral infections.
7 Because there is a great need for the development of novel medicines 7, 8 and consequently also for NRTIs, we developed a synthetic route for 4′-C-alkylated-5-iodo-2′-deoxyuridines 3a-c and 4′-C-alkylated-5-iodo-2′-deoxycytidines 4a-c. We recently designed and synthesized a series of 4′-C-modified nucleosides and nucleotides. 6b,9 In this study we combined our knowledge with a literature known synthesis strategy for 1 10 and 12a 5b to synthesize the compounds 3a-c and converted those in turn into the 4′-C-alkylated-5-iodo-2′-deoxycytidines 4a-c. These novel nucleoside entities are of great interest, because they combine the structural features of the marketed drug 1 or 2, and 4′-C-modified nucleosides in one small molecule ( Figure 1 ).
Figure 1.
Chemical structures of 2′-deoxy-5-iodouridine 1, 2′-deoxy-5-iodocytidine 2, 4′-C-alkylated-5-iodo-2′-deoxyuridines 3a-c, and 4′-C-alkylated-5-iodo-2′-deoxycytidines 4a-c.
Results and Discussion
It is noteworthy to mention that 4′-C-modification of nucleosides always contain the generation of quaternary carbon centers including the restraints associated with the respective chemistry. To our knowledge, three main methodologies have been evolved for the synthesis of 4′-C-modified nucleosides. In methodology one a 4′-C-branch is attached to 2′-C-deoxynucleosides; Scheme 1. Synthesis of 2′-deoxy-4′-C-propyluridine 5c. Reagents and conditions: a) DMP, CH2Cl2, r.t., 91%; 9f b) EtPPh3Br, t-BuOK, THF, r.t., 84%; c) AcOH, Ac2O, H2SO4, r.t., 64%; d) uracil, BSA, TMSOTf, MeCN, reflux, 71%; e) NaOMe, MeOH, r.t.; f) PhOCSCl, DMAP, MeCN, r.t.; g) n-Bu3SnH, AIBN, toluene, reflux, 83% over 3 steps; h) 10% Pd/C, H2, EtOH, r.t.; i) TBAF, THF, r.t., 65% over 2 steps.
Here our synthesis strategy of 4′-C-modified nucleosides starts with the selective silylated 4-C-hydroxymethyl substituted ribose building block 6.
14 After conversion of 6, with Dess-Martin periodinane (DMP) 15 to the corresponding aldehyde, Wittig reaction allowed us C-C-bond formation to yield the 4-C-(Z)-prop-1-enyl ribose analogue 7c. Bulky alkoxides have previously been reported to be the bases of choice in Wittig reactions involving sterically encumbered substrates 9c, 16 and so we performed the reaction with potassium tert-butoxide (t-BuOK) and ethyltriphenylphosphonium bromide (EtPPh3Br) as C2-synthon. By protection group manipulations we converted 7c to the substituted ribosyl acetate 8c.
Next, according to Vorbrüggen glycosylation the nucleobase uracil was fused with the 4-Cmodified glycosyl donor 8c. 13 Reaction with bis(trimethylsilyl)uracil, which is formed as an intermediate by silylation of uracil with bis(trimethylsilyl)acetamide (BSA), and trimethylsilyl triflate (TMSOTf) as catalyst gave stereoselectively the -configurated 4′-C-(Z)-prop-1-enyl substituted nucleoside 9c. After deacetylation with sodium methoxide (NaOMe) and reaction with phenyl chlorothionoformate (PhOCSCl) in the presence of 4-dimethylaminopyridine (DMAP) we obtained the thiocarbonate ester, which was subsequently reduced with tributyltin hydride (n-Bu3SnH) to the 2′-deoxyuridine analogue 10c. Catalytic hydrogenation with Pd/C followed by desilylation with tetrabutylammonium fluoride (TBAF) furnished the 2′-deoxy-4′-Cpropyluridine 5c (Scheme 1).
After we had the analogues 5a-c in hand, we assigned a literature known synthesis strategy for 1 10 and 12a 5b to our routes. We acetylated 5a-c to yield compounds 11a-c. Diammonium cerium (IV) nitrate (CAN) mediated iodination (12a-c), followed by deprotection furnished in good to excellent yields the 4′-C-methyl-, 4′-C-ethyl-and 4′-C-propyl-5-iodo-2′-deoxyuridine analogues 3a-c (Scheme 2). Scheme 2. Synthesis of 2′-deoxy-5-iodouridine analogues 3a-c. Reagents and conditions: a) Et3N, Ac2O, DMAP, MeCN, r.t., 63% (11a), 74% (11b), 93% (11c); b) I2, CAN, MeCN, reflux, 89% (12a), 98% (12b), 89% (12c); c) NaOMe, MeOH, r.t., 91% (3a), 97% (3b), 97% (3c).
Our convergent synthetic strategy to synthesize the 4′-C-alkylated-5-iodo-2′-deoxycytidines 4a-c was based on the conversion of uridine or thymidine derivatives into the respective cytidine analogues.
9e,17 Thus, we silylated 3a-c with tert-butyldimethylsilyl chloride (TBDMSCl) in the presence of imidazole to yield compounds 13a-c. Afterwards 13a-c was converted into 14a-c by treatment with the 2,4,6-triisopropylbenzenesulfonyl chloride (TPSCl)-Et3N-DMAP system, and followed by aminolysis with ammonium hydroxide (NH4OH) to generate the exocyclic amino function. Finally, desilylation with TBAF yielded the 4′-C-methyl-, 4′-C-ethyl-and 4′-C-propyl-5-iodo-2′-deoxycytidine analogues 4a-c (Scheme 3).
Scheme 3. Synthesis of 2′-deoxy-5-iodocytidine analogues 4a-c. Reagents and conditions: a) TBDMSCl, imidazole, DMF, r.t., 81% (13a), 90% (13b), 91% (13c); b) TPSCl, DMAP, Et3N, MeCN, r.t.; c) 28% NH4OH, 78% (14a), 77% (14b), 80% (14c) over 2 steps; d) TBAF, THF, r.t., 92% (4a), 89% (4b), 81% (4c).
Conclusions
In conclusion, we synthesized, starting from the available ribose-building block 6, the 4′-Cmethyl-, 4′-C-ethyl-and the new 4′-C-propyl-substituted deoxyuridines 5a-c. Afterwards we synthesized starting with 5a-c the corresponding 4′-C-alkylated-5-iodo-2′-deoxyuridines 3a-c and converted those into the 4′-C-alkylated-5-iodo-2′-deoxycytidines 4a-c. The novel nucleoside analogues 3a-c and 4a-c are 4′-C-alkylated derivatives of the approved antiviral drugs 2′-deoxy-5-iodouridine 1 and 2′-deoxy-5-iodocytidine 2. Due to the fact, that several derivatives of 4′-Cmodified nucleosides also showed antiviral activity, the here reported molecules are generally of great interest because of their potential antiviral activities. Additionally the herein reported molecules could act as useful synthetic building blocks for further 4′-C-modified nucleosides.
Experimental Section
General. All reagents are commercially available and used without further purification. MeCN was dried by distillation from CaH2. All other solvents are dried over molecular sieves and used directly without further purification. All reactions were conducted under exclusion of air and moisture. Petroleum ether (PE) used had a b.p. range of 35-80 °C. NMR spectra: Bruker Avance III 400 MHz spectrometer. 1 H and 13 C chemical shifts are reported relative to the residual solvent peak. Flash chromatography: Merck silica gel G60. TLC: Merck precoated plates (silica gel 60 F254). ESI-IT: Bruker Esquire 3000 plus. HRMS: Bruker Daltronics micrOTOF-Q II ESI-Qq-TOF. The reported yield refers to the analytically pure substance and is not optimized. Building block 6 was synthesized according to literature.
14 Compounds 5a-b were prepared as we described recently. 2 mmol) and the mixture was stirred at r.t. over night. After completion of the reaction, the mixture was quenched with aq sat. NaHCO3 solution (60 mL). The organic layer was separated and the aqueous layer was extracted with CH2Cl2 (4×20 mL). The organic layers were combined, dried over MgSO4, concentrated and purified by silica gel column chromatography (EtOAc-PE, 1:9) as eluent to give the aldehyde intermediate as a white solid (yield 17.78 g, 91%). Next, EtPPh3Br (23.43 g, 63.1 mmol) and t-BuOK (10.78 g, 96.0 mmol) were suspended in THF (100 mL) and stirred at r.t. for 2 h. Then the synthesized aldehyde (15.00 g, 27.4 mmol) in THF (20 mL) was added and stirring was continued for 17 h. The reaction mixture was quenched with aq sat. NaHCO3 solution (40 mL) and extracted with CH2Cl2 (3×60 mL). The combined organic layers were dried over MgSO4, concentrated and purified by silica gel column chromatography (EtOAc-PE, 1:6) to give 7c. Yellow gum, yield 12.86 g, 84%, Rf 0.55 (EtOAc-PE, 1:4). 14.79, 19.48, 25.58, 26.48, 27.01, 64.58, 72.76, 78.37, 86.54, 100.23, 103.91, 113.36, 126.97, 127.76, 127.87, 128.03, 128.05, 128.63, 128.65, 129.81, 129.81, 133.27, 133.94, 135.02, 135.75, 136.09, + calcd for C34H42O5Si: 581.3; found: 581.1.
1,2-Di-O-acetyl-3-O-benzyl-5-(O-tert-butyldiphenylsilyl)-4-C-(Z)-prop-1-enyl-,-D-ribofuranose (8c)
. To a solution of compound 7c (12.80 g, 22.9 mmol) in a mixture of AcOH (208 mL) and Ac2O (32.4 mL, 247.7 mmol) was added concd H2SO4 (200 L) and the mixture was stirred for 24 h at r.t. After completion of the reaction, the mixture was concentrated and coevaporated with toluene (2 × 100 mL). The residue was diluted with CH2Cl2 (100 mL) and washed with aq sat. NaHCO3 (25 mL) and demin. H2O (25 mL), dried over MgSO4, concentrated, and purified by silica gel column chromatography (EtOAc-PE, 1:4) to give 8c. 14.45, 19.58, 20.98, 21.17, 27.05, 65.07, 73.55, 74.82, 76.69, 88.78, 98.24, 100.20, 126.35, 127.82, 127.86, 127.96, 128.01, 128.50, 128.60, 129.86, 129.97, 133.40, 135.01, 135.79, 135.84, 138.02, 169.71, 170.20 19.41, 20.74, 27.04, 64.13, 73.87, 74.19, 75.81, 77.21, 87.11, 87.98, 100.01, 102.63, 124.43, 127.72, 127.95, 128.01, 128.03, 128.48, 130.08, 130.12, 130.18, 132.13, 132.94, 135.34, 135.62, 137.31, 139.77, 149.75, 162.42, 169.94 
2′-O-Acetyl-3′-O-benzyl-5′-(O-tert-butyldiphenylsilyl)-4′-C-(Z)-prop-1-enyluridine (9c

. ESI-MS: m/z [M+Na]
+ calcd for C37H42N2O7Si: 677.3; found: 677.9.
3′-O-Benzyl-5′-(O-tert-butyldiphenylsilyl)-2′-deoxy-4′-C-(Z)-prop-1-enyluridine (10c).
Compound 9c (5.88 g, 9.0 mmol) was solved in MeOH (100 mL) and NaOMe (0.73 g, 13.5 mmol) was added. The mixture was stirred at r.t. for 2 h. After completion of the reaction, the mixture was treated with aq concd tartaric acid (50 mL) and extracted with CH2Cl2 (3×80 mL). The combined organic layers were dried over MgSO4, concentrated and purified by silica gel column chromatography (EtOAc-PE, 4:1). The resulting compound was dissolved in MeCN (65 mL), DMAP (3.31 g, 27.0 mmol) and PhOCSCl (1.5 mL, 10.8 mmol) were added and the mixture was stirred at r.t. for 1 h. After completion of the reaction the mixture was concentrated, diluted in CH2Cl2 (60 mL), washed with aq 5% citric acid (30 mL) and demin. H2O (20 mL). The aqueous layer was extracted with CH2Cl2 (50 mL), the combined organic layers dried over MgSO4 and evaporated. To a solution of the residue in toluene were added n-Bu3SnH (12.57 g, 43.2 mmol) and a catalytic amount of AIBN. The mixture was refluxed for 1 h. After completion of the reaction the solvent was removed under reduced pressure and the residue was purified by silica gel column chromatography (EtOAc-PE, 3:7) to give 10c. White foam, yield 4.44 g, 83%, Rf 0.31 (EtOAc-PE, 1:1 14.30, 19.63, 27.26, 37.80, 64.50, 72.75, 75.66, 77.43, 83.20, 88.99, 100.21, 102.19, 124.68, 127.71, 128.15, 128.18, 128.21, 128.75, 130.25, 130.34, 131.65, 132.46, 133.20, 135.55, 135.79, 137.79, 140.43, 150.17, + calcd for C35H40N2O5Si: 619.3; found: 619.6.
2′-Deoxy-4′-C-propyluridine (5c)
. To a solution of compound 10c (4.06 g, 7.1 mmol) in EtOH (50 mL) was added an equivalent weight amount of 10% Pd/C and the mixture was stirred at r.t. for 8 h under H2 atmosphere (balloon). After completion of the reaction the mixture was filtered through Celite on a sintered funnel and washed thoroughly. The solvent was removed and the residue was dissolved in THF (40 mL) and a 1 M solution of TBAF (9.1 mL, 9.1 mmol) was added. The mixture was stirred at r.t. for 16 h, concentrated and purified by silica gel column chromatography (EtOAc→MeOH-EtOAc, 1:9) to give 5c. 
General synthetic procedure, exemplified by 3′,5′-di-O-acetyl-2′-deoxy-4′-C-methyluridine (11a)
To a suspension of compound 5a (0.62 g, 2.56 mmol) in MeCN (14 mL) was added NEt3 (1.43 mL, 10.2 mmol), Ac2O (0.96 mL, 10.2 mmol) and a catalytic amount of DMAP. The mixture was stirred at r.t. for 20 h and then diluted with CH2Cl2 (40 mL) and washed with demin. H2O (3×30 mL). The organic layer was dried over MgSO4, concentrated and purified by silica gel column chromatography (EtOAc-PE, 6:1 40, 20.92, 20.95, 38.71, 67.98, 73.82, 84.21, 85.08, 102.84, 139.02, 150.44, 163.19, 170.21 
. ESI-MS: m/z [M+Na]
+ calcd for C14H18N2O7: 349.1; found: 349.3. 14.87, 17.12, 21.07, 21.09, 34.36, 39.05, 66.49, 74.10, 84.37, 86.81, 102.88, 139.09, 150.28, 162.82, 170.17, + calcd for C16H22N2O7: 377.1; found: 377.3.
3′,5′-Di-O-acetyl-2′-deoxy-4′-C-ethyluridine (11b
3′,5′-Di-O-acetyl-2′-deoxy-4′-C-propyluridine (11c
General synthetic procedure, exemplified by 3′,5′-di-O-acetyl-2′-deoxy-5-iodo-4′-C-methyluridine (12a)
Compound 11a (0.46 g, 1.40 mmol), iodine (0.21 g, 0.84 mmol) and CAN (0.38 g, 0.70 mmol) were solved in MeCN (23 mL) and refluxed for 1 h. After completion of the reaction the solvent was removed under reduced pressure and the residue was partitioned between EtOAc (40 mL), aq sat. NaCl (20 mL) and aq 5% NaHSO4 (5 mL). The aqueous layer was extracted with EtOAc (2×40 mL) and the combined organic layers were washed first with aq 5% NaHSO4 (5 mL) and then with aq sat. NaCl (25 mL) and demin. H2O (2×15 mL), dried over MgSO4, concentrated and purified by silica gel column chromatography (EtOAc-PE, 2:1). 01, 20.92, 21.36, 24.95, 39.27, 66.19, 68.86, 73.60, 84.43, 87.10, 143.98, 150.20, 160.04, 170.08, + calcd for C15H19IN2O7: 489.0; found: 489.1. 2.33 (dt, J 14.3, 7.0 Hz, 1H), 2.47 (ddd, J 14.4, 6.2, 3.8 Hz, 1H), 4.16 (d, J 12.4 Hz, 1H), 4.19 (d, J 12.4 Hz, 1H), 5.34 (dd, J 7.0, 3.8 Hz, 1H), 6.17 (t, J 6.6 Hz, 1H), 7.99 (s, 1H), 9.41 (s, 1H).
3′,5′-Di-O-acetyl-2′-deoxy-5-iodo-4′-C-ethyluridine (12b
3′,5′-Di-O-acetyl-2′-deoxy-5-iodo-4′-C-propyluridine (12c
13 C NMR (101 MHz, CDCl3): δ 14.83, 17.10, 21.01, 21.46, 34.42, 39.35, 66.61, 68.91, 73.69, 84.50, 87.06, 144.05, 150.22, 160.03, 170.16, + calcd for C16H21IN2O7: 503.0; found: 503.4.
General synthetic procedure, exemplified by 2′-deoxy-5-iodo-4′-C-methyluridine (3a)
Compound 12a (0.08 g, 0.17 mmol) was stirred with 0.1 M NaOMe/MeOH (8 mL) at r.t. for 1 h. After the reaction was completed, addition of 2 mL of demin. H2O was followed by neutralization (pH 6) with Amberlite IR-120 (H + form) ion-exchange resin. The resin was filtered and washed with 50% aq MeOH (20 mL). The combined filtrate and washings were evaporated and purified by silica gel column chromatography (EtOAc). 
General synthetic procedure, exemplified by 3′,5′-di-(O-tert-butyldimethylsilyl)-2′-deoxy-5-iodo-4′-C-methyluridine (13a)
To a solution of 3a (0.463 g, 1.26 mmol) in DMF (3 mL) TBDMSCl (1.22 g, 8.1 mmol) and imidazole (0.81 g, 11.6 mmol) were added. The clear solution was stirred at r.t. for 60 h. Demin. H2O (15 mL) was added, the aqueous layer was extracted with EtOAc (4×50 mL), dried over MgSO4, concentrated and purified by silica gel column chromatography (EtOAc-PE, 1:4 2.18 (ddd, J 13.4, 7.4, 6.2 Hz, 1H), 2.33 (ddd, J 13.2, 5.9, 3.1 Hz, 1H), 3.55 (d, J 10.9 Hz, 1H), 3.71 (d, J 10.9 Hz, 1H), 4.33 (dd, J 6.1, 3.1 Hz, 1H), 6.18 (dd, J 7.3, 6.0 Hz, 1H), 8.13 (s, 1H), 8.17 (s, 1H) . 13 C NMR (101 MHz, 18.21, 18.50, 18.72, 25.87, 26.36, 42.63, 68.04, 68.24, 73.08, 84.94, 89.15, 144.77, 149.74, + calcd for C22H41IN2O5Si2: 619.2; found: 619.0. 14.8, 7.5 Hz, 1H), 1.74 (dq, J 15.1, 7.6 Hz, 1H), 1H), 2.31 (ddd, J 13.2, 5.9, 2.9 Hz, 1H), 3.57 (d, J 10.8 Hz, 1H), 3.74 (d, J 10.8 Hz, 1H), 4.40 (dd, J 6.2, 2.9 Hz, 1H), 6.16 (dd, J 7.5, 6.0 Hz, 1H), 8.11 (s, 1H), 8.26 (s, 1H) . 13 C NMR (101 MHz, 8.41, 18.17, 18.68, 24.96, 25.88, 26.35, 42.69, 66.34, 68.14, 73.38, 84.98, 90.62, 144.76, 149.79, + calcd for C23H43IN2O5Si2: 633.2; found: 633.1. 2.31 (ddd, J 13.2, 5.9, 2.9 Hz, 1H), 3.56 (d, J 10.9 Hz, 1H), 3.74 (d, J 10.9 Hz, 1H), 4.38 (dd, J 6.2, 2.9 Hz, 1H), 6.16 (dd, J 7.5, 6.0 Hz, 1H), 8.11 (s, 1H), 8.59 (s, 1H) .
3′,5′-Di-(O-tert-butyldimethylsilyl)-2′-deoxy-5-iodo-4′-C-ethyluridine (13b
3′,5′-Di-(O-tert-butyldimethylsilyl)-2′-deoxy-5-iodo-4′-C-propyluridine (13c
13
C NMR (101 MHz, 14.95, 17.24, 18.17, 18.68, 25.79, 25.87, 26.35, 34.75, 42.68, 66.72, 68.20, 73.42, 84.99, 90.53, 144.75, 149.93, 160.05 -4.98, -4.45, 18.16, 18.32, 18.66, 25.87, 26.32, 42.84, 55.91, 67.83, 72.50, 85.78, 88.82, 146.79, 154.88, 163.84 -4.37, 8.31, 18.11, 18.61, 24.63, 25.87, 26.30, 42.96, 56.11, 65.83, 72.87, 85.78, 90.28, 146.73, 154.91, 163.89 -5.02, -5.01, -4.39, 14.95, 17.15, 18.11, 18.60, 25.86, 26.29, 34.42, 42.97, 56.20, 66.23, 72.59, 85.79, 90.21, 146.68, 154.93, 163.94 15.26, 18.09, 34.81, 42.38, 56.55, 64.83, 71.84, 86.82, 91.13, 149.41, 157.36, 165.84 
